Comparison between Euro Pratik Sales IPO and Veeda Clinical Research IPO.
Euro Pratik Sales IPO is a Mainboard Bookbuilding IPO proposed to list at BSE, NSE while Veeda Clinical Research IPO is a Mainboard Bookbuilding proposed to list at BSE, NSE.
The total issue size of Euro Pratik Sales IPO is up to ₹451.31 Cr whereas the issue size of the Veeda Clinical Research IPO is up to ₹0.00 Cr. The final issue price of Euro Pratik Sales IPO is ₹247.00 per share and of Veeda Clinical Research IPO is .
| Euro Pratik Sales IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Face Value | ₹1 per share | ₹2 per share |
| Issue Price (Lower) | ₹235.00 per share | |
| Issue Price (Upper) | ₹247.00 per share | |
| Issue Price (Final) | ₹247.00 per share | |
| Discount (Retail) | ||
| Discount (Employee) | ₹13.00 per share | |
| Market Lot Size | 60 shares | |
| Fresh Issue Size | 0 shares | 0 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹185.00 Cr |
| OFS Issue Size | 1,82,74,798 shares | 1,30,08,128 shares |
| OFS Issue Size (Amount) | up to ₹451.31 Cr | up to ₹0.00 Cr |
| Issue Size Total | 1,82,74,798 shares | 0 shares |
| Issue Size Total (Amount) | up to ₹451.31 Cr | up to ₹0.00 Cr |
Euro Pratik Sales IPO opens on Sep 16, 2025, while Veeda Clinical Research IPO opens on . The closing date of Euro Pratik Sales IPO and Veeda Clinical Research IPO is Sep 18, 2025, and , respectively.
| Euro Pratik Sales IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Bid Date | Sep 15, 2025 | |
| Issue Open | Sep 16, 2025 | |
| Issue Close | Sep 18, 2025 | |
| Basis Of Allotment (Tentative) | Sep 19, 2025 | |
| Initiation of Refunds (Tentative) | Sep 22, 2025 | |
| Credit of Share (Tentative) | Sep 22, 2025 | |
| Listing date (Tentative) | Sep 23, 2025 | |
| Anchor Lockin End date 1 | Oct 18, 2025 | |
| Anchor Lockin End date 2 | Dec 17, 2025 |
Euro Pratik Sales IPO P/E ratio is 33.02, as compared to Veeda Clinical Research IPO P/E ratio of .
| Euro Pratik Sales IPO | Veeda Clinical Research IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated Consolidated)Euro Pratik Sales Ltd.'s revenue increased by 27% and profit after tax (PAT) rose by 22% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated Consolidated)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 87.97 | 33.83 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | 70.1 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | 33.02 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ₹2524.34 Cr. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 39.18% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 44.58% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.01 | 0.32 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ₹7.48 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 32.60% | -0.02% | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Euro Pratik Sales IPO Retail Individual Investors (RII) are offered 63,75,313 shares while in Veeda Clinical Research IPO retail investors are offered 63,75,313 shares. Qualified Institutional Buyers (QIB) are offered 36,43,036 shares in Euro Pratik Sales IPO and in Veeda Clinical Research IPO.
| Euro Pratik Sales IPO | Veeda Clinical Research IPO | |
|---|---|---|
| Anchor Investor Reservation | 54,64,554 shares | |
| Market Maker Reservation | 0 shares | |
| QIB | 36,43,036 shares | |
| NII | 27,32,277 shares | |
| RII | 63,75,313 shares | |
| Employee | 59,827 shares | |
| Others | ||
| Total | 1,82,75,007 shares |
Euro Pratik Sales IPO subscribed 1.41x in total, whereas Veeda Clinical Research IPO subscribed .
| Euro Pratik Sales IPO | Veeda Clinical Research IPO | |
|---|---|---|
| QIB (times) | 1.10x | |
| NII (times) | 2.02x | |
| Big NII (times) | 2.35x | |
| Small NII (times) | 1.35x | |
| RII (times) | 1.31x | |
| Employee (times) | 4.09x | |
| Other (times) | ||
| Total (times) | 1.41x |
